CCI approves merger of Serum Institute subsidiaries Biocon Biologics and CTPL
New Delhi: The Competition Commission of India (CCI) has approved the merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for the acquisition of approximately 15 percent equity shareholding of Biocon Biologics by Serum Institute Life Sciences.
SII buys 50 pc stake in pharma packaging firm Schott Kaisha
Pune/IBNS: Pune-based manufacturer of AstraZeneca vaccine, Covishield, Serum Institute of India (SII) has acquired a 50 per cent stake in SCHOTT Kaisha to become SCHOTT's joint venture partner and secure the pharma packaging supply, the pharma company announced on Tuesday.
Boris Johnson announces Serum Institute of India to invest 240 million pounds in UK
London: British PM Boris Johnson has announced the Serum Institute of India (SII), the manufacturers of COVID-19 vaccine Covishield, will be investing 240 million pounds in the United Kingdom through the opening of a new sales office, media reports said.